ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Form 10-Q November 09, 2010 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2010

OR

" TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 000-32085

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Edgar Filing: ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. - Form 10-Q

Delaware (State or other jurisdiction of

36-4392754 (I.R.S. Employer

incorporation or organization)

Identification Number)

222 Merchandise Mart, Suite 2024

Chicago, IL 60654

(Address of principal executive offices)

(866) 358-6869

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes "No"

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer x Accelerated filer

Non-accelerated filer " (Do not check if a smaller reporting company)

Smaller reporting company
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes " No x

As of November 2, 2010, there were 186,258,545 shares of the registrant s \$0.01 par value common stock outstanding.

Table of Contents

Explanatory Note

On August 24, 2010, Allscripts-Misys Healthcare Solutions, Inc. (which changed its name to Allscripts Healthcare Solutions, Inc., Allscripts) completed the transactions contemplated by an Agreement and Plan of Merger dated June 9, 2010 by and among Allscripts-Misys Healthcare Solutions, Inc., Arsenal Merger Corp., a wholly-owned subsidiary of Allscripts, and Eclipsys Corporation (Eclipsys). Eclipsys became a wholly-owned subsidiary of Allscripts as a result of the merger. The results of Eclipsys are consolidated with the results of Allscripts from August 24, 2010. The merger is described in greater detail within this Form 10-Q. On August 23, 2010, the Board of Directors approved a change of fiscal year end from May 31 to December 31. As a result of this change, Allscripts is filing this quarterly report on Form 10-Q for the three and nine month periods ended September 30, 2010. Comparative financial results are provided for the three and nine month periods ended August 31, 2009.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

FORM 10-Q

INDEX

PART I.	FINANCIAL INFORMATION	PAGE
Item 1.	Financial Statements (unaudited)	
	Consolidated Balance Sheets at September 30, 2010, May 31, 2010 and December 31, 2009	3
	Consolidated Statements of Operations for the three and nine months ended September 30, 2010 and August 31, 2009	4
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2010 and August 31, 2009	5
	Notes to Consolidated Financial Statements	6
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	25
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	44
Item 4.	Controls and Procedures	44
PART II.	OTHER INFORMATION	44
Item 1.	<u>Legal Proceedings</u>	44
Item 2.	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities	44
Item 5.	Other Information	44
Item 6.	<u>Exhibits</u>	44
SIGNAT	URES	45

2

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)

(Unaudited)

	September 30, 2010		May 31, 2010		December 31, 2009	
ASSETS						
Current assets:						
Cash and cash equivalents	\$	120,067	\$	143,410	\$	81,301
Restricted cash		2,225		0		0
Accounts receivable, net of allowance of \$11,673, \$8,531 and \$6,984 at September 30,						
2010, May 31, 2010 and December 31, 2009, respectively		308,377		181,920		160,566
Deferred taxes, net		14,546		29,042		1,684
Inventories		4,303		3,184		3,898
Prepaid expenses and other current assets		100,642		50,598		45,622
Total current assets		550,160		408,154		293,071
Long-term marketable securities		1,778		1,925		1,896
Fixed assets, net		101,623		24,637		18,494
Software development costs, net		45,008		29,900		21,564
Intangible assets, net		558,721		206,642		215,398
Goodwill		1,051,234		413,390		413,390
Other assets		69,119		10,042		12,009
Total assets	\$	2,377,643	\$ 1	1,094,690	\$	975,822
LIABILITIES AND STOCKHOLDERS EQUITY						
Current liabilities:						
Accounts payable	\$	42,739	\$	32,295	\$	7,408
Accrued expenses		76,025		56,495		45,451
Accrued compensation and benefits		41,249		18,206		13,977
Deferred revenue		200,420		103,984		89,290
Other current liabilities		24,827		1,113		731
Total current liabilities		385,260		212,093		156,857
Long-term debt		506,500		0		23,995
Deferred revenue		5,930		0		0
Deferred taxes, net		63,143		71,264		22,377
Other liabilities		48,327		4,508		4,001
		-,		,		,
Total liabilities		1,009,160		287,865		207,230

Edgar Filing: ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. - Form 10-Q

Commitments and contingencies					
Stockholders equity:					
Preferred stock:					
Undesignated, \$0.01 par value, 1,000 shares authorized, no shares issued and outstanding					
at September 30, 2010, May 31, 2010 and December 31, 2009		0	0		0
Common stock:					
\$0.01 par value, 349,000 shares authorized; 247,937 and 186,148 shares issued and					
outstanding at September 30, 2010, respectively, 146,367 shares issued and outstanding at					
May 31, 2010, 145,971 shares issued and outstanding at December 31, 2009		2,479	1,464		1,460
Treasury stock, 61,308 shares at cost		(613)	0		0
Additional paid-in capital		1,449,946	889,738		883,947
Accumulated deficit		(83,763)	(84,421)		(116,803)
Accumulated other comprehensive income/(loss)		434	44		(12)
Total stockholders equity		1,368,483	806,825		768,592
		, ,	,-		,
Total liabilities and stockholders equity	\$	2,377,643	\$ 1,094,690	\$	975,822

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

${\bf ALLSCRIPTS\ HEALTHCARE\ SOLUTIONS, INC.}$

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended		Nine Months Ended		
	September 30, 2010	August 31, 2009	September 30, 2010	August 31, 2009	
Revenue:					
System sales	\$ 46,913	\$ 33,457	\$ 135,573	\$ 98,135	
Professional services	38,948	15,918	82,341	48,557	
Maintenance	76,827	59,419	206,472	172,215	
Transaction processing and other	79,705	56,116	193,772	163,318	
Total software and related services	242,393	164,910	618,158	482,225	
Prepackaged medications	0	0	0	9,721	
Total revenue	242,393	164,910	618,158	491,946	
Cost of revenue:	2 12,333	101,510	010,120	151,510	
System sales	22,199	19,579	70,250	52,203	
Professional services	33,556	15,503	71,553	48,472	
Maintenance	26,806	20,949	68,352	61,258	
Transaction processing and other	35,420	19,809	74,961	57,923	
Total software and related services	117,981	75,840	285,116	219,856	
Prepackaged medications	0	0	0	7,626	
Total cost of revenue	117,981	75,840	285,116	227,482	
Total cost of Teveniue	117,961	73,040	265,110	221,402	
Gross profit	124,412	89,070	333,042	264,464	
Selling, general and administrative expenses	103,826	52,959	227,165	155,849	
Research and development	16,697	11,978	44,545	32,524	
Amortization of intangible assets	5,576	2,563	10,552	8,004	
(Loss) income from operations	(1,687)	21,570	50,780	68,087	
Interest expense	(3,069)	(685)	(3,851)	(2,142)	
Interest income and other, net	250	101	979	432	
interest meome and other, net	230	101	919	732	
(Loss) income before income taxes	(4,506)	20,986	47,908	66,377	
Benefit (provision) for income taxes	5,879	(8,054)	(14,868)	(26,829)	
Net income	\$ 1,373	\$ 12,932	\$ 33,040	\$ 39,548	
Earnings per share:					